| 000 | 01646 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250512203241.0 | ||
| 264 | 0 | _c19840801 | |
| 008 | 198408s 0 0 eng d | ||
| 022 | _a0077-8923 | ||
| 024 | 7 |
_a10.1111/j.1749-6632.1984.tb12280.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPullen, D J | |
| 245 | 0 | 0 |
_aPediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. _h[electronic resource] |
| 260 |
_bAnnals of the New York Academy of Sciences _c1984 |
||
| 300 |
_a26-48 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAntigens, Neoplasm _xanalysis |
| 650 | 0 | 4 |
_aBone Marrow _ximmunology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHistocompatibility Antigens Class II _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xanalysis |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aLeukemia, Lymphoid _xclassification |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeprilysin |
| 650 | 0 | 4 | _aPrognosis |
| 700 | 1 | _aBoyett, J M | |
| 700 | 1 | _aCrist, W M | |
| 700 | 1 | _aFalletta, J M | |
| 700 | 1 | _aRoper, M | |
| 700 | 1 | _aDowell, B | |
| 700 | 1 | _aVan Eys, J | |
| 700 | 1 | _aJackson, J F | |
| 700 | 1 | _aHumphrey, G B | |
| 700 | 1 | _aMetzgar, R S | |
| 773 | 0 |
_tAnnals of the New York Academy of Sciences _gvol. 428 _gp. 26-48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1749-6632.1984.tb12280.x _zAvailable from publisher's website |
| 999 |
_c6234815 _d6234815 |
||